The purpose of this study is to evaluate the effectiveness, safety and tolerability of MN given to ALS participants for 12 months followed by a 6-month open-label extension phase.
The goals of this study are to identify biomarkers that allow improved staging or prognosis of the disease, and through the discovery of previously unrecognized immune abnormalities in ALS we aim to eventually identify immune therapies that may provide benefit in ALS. The purpose of this study is to identify patients with a diagnosis of Amyotrophic Lateral Disease ALS or ALS variants who have laboratory markers of inflammation or autoimmunity.
Recent evidence suggests that some patients with ALS who have laboratory markers of inflammation may respond to therapies that modulate immune system function. The aim of this study is to determine what percentage of patients with ALS and ALS variants have positive laboratory markers of inflammation or autoimmunity. The purpose of this study is to evaluate the effect of retigabine dosages on motor neuron activity in people with Amyotrophic Lateral Sclerosis ALS.
The purpose of this study is to evaluate the safety and effectiveness of NP for treating patients who have amyotrophic lateral sclerosis ALS and evidence of systemic inflammation. The purpose of this study is to assess the long-term safety and tolerability of tirasemtiv in patients with ALS. This study will evaluate whether prolonged oral levosimendan can preserve respiratory function more effectively than placebo, resulting in better patient functionality as measured by the ALSFRS-R scale. In this randomized, double-blind, placebo-controlled, parallel-group, multicenter study, subjects are allocated in a ratio to receive either levosimendan 1 -2 mg daily or placebo for 48 weeks.
Other important efficacy measures include time to respiratory events, clinical global This first-in-human, double-blind, placebo-controlled Phase I study will be conducted in participants with amyotrophic lateral sclerosis ALS to explore safety, tolerability, and pharmacokinetic PK properties of GDC The purpose of this study is to evaluate the safety and effectiveness of investigational products for the treatment of ALS.
The purpose of this study is to assess the effect of CK versus placebo on respiratory function and other measures of skeletal muscle function in patients with ALS. A bone marrow aspiration will be required as part of this program. It will take about 30 weeks for participants to complete the program. The purpose of this study is to determine determine the safety of intraspinal delivery of mesenchymal stem cells MSCs to the cerebral spinal fluid of patients with Amyotrophic Lateral Sclerosis ALS using a dose-escalation study.
The purpose of this study is to collect biofluid samples for the banking and usage in ALS research. Through comparison of these samples, the researchers hope to learn more about the underlying cause of ALS, as well as find unique biological markers, which could be used to develop new therapies.
The purpose of this study is to evaluate the potential to use TMS as a way of functionally assessing target engagement in an efficacy study of Perampanel as a treatment for ALS.
Any use of this site constitutes your agreement to the Terms and Conditions and Privacy Policy linked below. Mayo Clinic is a nonprofit organization and proceeds from Web advertising help support our mission. Mayo Clinic does not endorse any of the third party products and services advertised. A single copy of these materials may be reprinted for noncommercial personal use only. However, there are many different kinds of stem cells from all parts of the body that each have different purposes, so scientists first had to do preclinical research to determine which cells would be best to use in regenerating heart muscle.
When put in an environment like the heart, those growth factors act like fertilizer and can stimulate new heart muscle to grow bigger. Decades of research has been done using stem cells to treat heart disease, but almost all of the research has been in adults, not in children or people with congenital heart defects. The first step in testing any new treatment or drug is to start with a small group of subjects in a Phase I, or pilot study.
The goal of a Phase I study is very simple — make sure the new treatment is safe. MNCs are also found in bone marrow, but harvesting bone marrow from an infant is challenging and risky. So researchers decided to collect UCB from the baby at birth and harvest the cells from there. Because of this novel approach to collecting and processing UCB, this Phase I study also had an additional goal of making sure the entire process was feasible.
Other autoimmune diseases of the nervous system. As with multiple sclerosis, using the patient's own stem cells might stop disease progression. For other diseases, though, aggressive immunotherapies are available that could mitigate the need for autologous stem cell transplant. Advertising Mayo Clinic is a nonprofit organization and proceeds from Web advertising help support our mission. Advertising and sponsorship policy Advertising and sponsorship opportunities.
Reprint Permissions A single copy of these materials may be reprinted for noncommercial personal use only.
0コメント